The complaint filed against Chemours centers on claims that the company violated the Securities Exchange Act of 1934. According to the allegations, the firm artificially boosted market perceptions by overselling its Opteon products during the prior fiscal year, subsequently overstating aftermarket demand throughout the current period. These actions led to public statements that were reportedly false and materially misleading to shareholders.

Investors seeking to participate in the recovery process have until December 7, 2026, to take action. The DJS Law Group, which specializes in securities litigation and corporate governance, is currently vetting shareholders for potential lead plaintiff appointments. Participation in the litigation does not require a formal lead plaintiff designation, though affected parties are encouraged to reach out to the firm to evaluate their specific losses.